The nation's top infectious diseases expert says he expects the U.S. Food and Drug Administration to quickly approve a new experimental drug that showed promising signs in treating patients with COVID-19.
Anthony Fauci tells NBC's Today show Thursday that he anticipates the go-ahead for the emergency use of Remdesivir to happen really quickly. He says he spoke with FDA Commissioner Stephen Hahn on Wednesday, and while Hahn had yet to make a final decision, I would project that we're going to be seeing that reasonably soon.
The drug was shown in a major study to shorten recovery time of hospitalized patients.
Fauci said the drug's manufacturer has committed to scaling production of the drug as quickly as possible as the world hunts for an effective treatment and ultimately a vaccine. Fauci has been working on a project to fast track the development of a vaccine by mass producing formulas that appear safe and effective before they're fully vetted. The goal is to get hundreds of millions of doses to the public by January.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
